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Towards High-throughput Immunomics for
Infectious Diseases: Use of Next-generation
Peptide Microarrays for Rapid Discovery and
Mapping of Antigenic Determinants*□S
Santiago J. Carmona‡, Morten Nielsen‡§, Claus Schafer-Nielsen¶, Juan Mucci‡,
Jaime Altcheh, Virginia Balouz‡, Valeria Tekiel‡, Alberto C. Frasch‡,
Oscar Campetella‡, Carlos A. Buscaglia‡, and Ferna´n Agu¨ero‡**
Complete characterization of antibody specificities asso-
ciated to natural infections is expected to provide a rich
source of serologic biomarkers with potential applica-
tions in molecular diagnosis, follow-up of chemothera-
peutic treatments, and prioritization of targets for vaccine
development. Here, we developed a highly-multiplexed
platform based on next-generation high-density peptide
microarrays to map these specificities in Chagas Disease,
an exemplar of a human infectious disease caused by the
protozoan Trypanosoma cruzi. We designed a high-den-
sity peptide microarray containing more than 175,000
overlapping 15mer peptides derived from T. cruzi pro-
teins. Peptides were synthesized in situ on microarray
slides, spanning the complete length of 457 parasite pro-
teins with fully overlapped 15mers (1 residue shift).
Screening of these slides with antibodies purified from
infected patients and healthy donors demonstrated both a
high technical reproducibility as well as epitope mapping
consistency when compared with earlier low-throughput
technologies. Using a conservative signal threshold to
classify positive (reactive) peptides we identified 2,031
disease-specific peptides and 97 novel parasite antigens,
effectively doubling the number of known antigens and
providing a 10-fold increase in the number of fine mapped
antigenic determinants for this disease. Finally, further
analysis of the chip data showed that optimizing the
amount of sequence overlap of displayed peptides can in-
crease the protein space covered in a single chip by at least
threefold without sacrificing sensitivity. In conclusion, we
show the power of high-density peptide chips for the dis-
covery of pathogen-specific linear B-cell epitopes from clin-
ical samples, thus setting the stage for high-throughput
biomarker discovery screenings and proteome-wide stud-
ies of immune responses against pathogens. Molecular &
Cellular Proteomics 14: 10.1074/mcp.M114.045906, 1871–
1884, 2015.
Detailed knowledge of antigens and epitopes recognized in
the context of naturally acquired human infections has impor-
tant implications for our understanding of immune system
responses against pathogens, and of the immunopathogen-
esis of infectious diseases. This knowledge is also important
for practical clinical applications such as the development of
improved vaccines, intervention strategies, and diagnostics.
In the last decades, significant progress has been made in
the discovery of antigens and epitopes thanks to a number of
methodologies such as cDNA expression libraries (1), combi-
natorial peptide libraries (2), and peptide and protein microar-
rays (3, 4). However, current knowledge of the B-cell antigens
and the epitope repertoire recognized by the immune system
in human infections is still scarce. Indeed, the Immune
Epitope Database (5) currently contains an average of only 10
antigens with mapped B-cell epitopes recognized from natu-
rally acquired human infections for bacterial or eukaryotic
pathogens. The reasons for this are many, but can be largely
attributed to different limitations in the mentioned screening
technologies. Heterologous expression of cDNA libraries has
been used to guide antigen discovery, but mapping of
epitopes most often lags behind as it is a much more costly
exercise. Similarly, combinatorial peptide libraries greatly fa-
cilitate the identification of peptides that are specifically rec-
ognized by antibodies, but these peptides have sequences
that can greatly differ from those of the native epitopes (they
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are mimotopes), thus making it difficult to identify the original
antigens. As a result, we currently have only limited detailed
information on the fine specificities of the antibody response
against complex pathogens.
The number of tools for studying immune responses has
recently expanded with the inclusion of peptide and protein
microarrays, which have been used to identify pathogen-
specific antigens and linear epitopes (6–13). Although whole-
protein arrays can successfully identify antigens recognized
by antibodies, they present the typical difficulties associated
with the production of recombinant proteins in heterologous
or in vitro systems, do not provide information on the nature
and precise location of the epitope(s) in a protein, and are
more likely to suffer from nonspecific antibody binding be-
cause of the exposure of a large number of potentially anti-
genic regions. In contrast, peptide arrays can provide exqui-
site detail of epitope localization, but until now had other
limitations mostly associated with their reduced capacity, pre-
venting the complete scanning of large numbers of candidate
proteins.
Recent advances in computerized photolithography and
photochemistry have led to the development of a novel high-
density peptide microarray technology, where individual pep-
tides can be synthesized in situ on a glass slide at high
densities (14–17). This technology makes the production of
high-density peptide arrays highly cost effective compared
with previous approaches, while allowing the interrogation of
complex immune responses with unprecedented throughput
and mapping precision. Previous applications of this technol-
ogy were limited to the fine mapping of epitopes in single
proteins, using monoclonal antibodies, or using immunized
animal sera as the source of polyclonal antibodies (16–18).
Using these high-density peptide arrays, we here describe
the first large-scale study of fine antibody specificities asso-
ciated with Chagas Disease, which is an exemplar of a chronic
human infectious disease. Chagas Disease, caused by the
protozoan Trypanosoma cruzi, is an endemic disease of the
Americas, affecting 8 million people (19). The parasite in-
vades and replicates within host cells, and briefly enters the
bloodstream to reach other target tissues. Initially, the disease
goes through an acute stage, characterized by patent para-
sitaemia and the appearance of antibodies against acute-
phase antigens, such as SAPA (20), followed by a delayed
specific humoral response. In general, the parasite-specific
immune response mounted during T. cruzi infections is insuf-
ficient to completely eradicate the pathogen, leading to
chronic infection (19). In this chronic stage circulating para-
sites are difficult to detect, even by extremely sensitive meth-
ods such as PCR. Therefore, detection of antibodies against
whole-parasite extracts or defined antigens (21, 22) remains
the standard for diagnosis of Chagas Disease.
In this work, we screened high-density microarray slides
containing peptides derived from T. cruzi proteins with mix-
tures of immunoglobulins purified directly from blood samples
of Chagas Disease patients. This led to the identification of
novel antigens and the simultaneous mapping of their linear
B-cell epitopes, thus demonstrating the capacity and per-
formance of this platform for studying antibody specificities
associated with human infectious diseases.
EXPERIMENTAL PROCEDURES
Peptide Microarray Content Design—A total of 457 T. cruzi protein
sequences annotated in the CL-Brener genome (version Jan. 2012)
(23) were selected for inclusion in the microarray (according to the
groups defined in Table I). Proteins in Group 1 were randomly sam-
pled from the proteome. If a sampled protein was a putative ortholog
of a previously picked protein (as defined by the OrthoMCL algorithm
(24)), that protein was skipped. Hence, the final protein set for this
group contained no homologous proteins. Group 2 contained T. cruzi
proteins without previous serology evidence, selected based on
shared features with known antigens such as evidence of expression,
subcellular localization, presence of tandem repeats, disordered re-
gions and B-cell epitope predictions, using an integrative method
developed in our group (25). Homologous proteins were removed
from this group, as described for Group 1. Group 3 is composed of
selected members of the MASP (mucin-associated surface proteins)
family. This is a multigene family composed of 1300 genes, with a
high level of polymorphisms (26, 27), localized at the surface of
infective forms of the parasite. This protein family has earlier been
proposed to participate in host-parasite interactions (28). The six
MASP subgroups (29) were represented in the group. Group 4 is
composed of 68 proteins with previous evidence of seroreactivity in T.
cruzi infected humans (these were obtained from the IEDB (5) or
manually curated from the literature), more information in supplemen-
tal Table S3. Protein Group 5 is composed by 54 neo-proteins of
random protein sequences. These random sequences have the same
mono- and di-peptide distribution as found in the T. cruzi proteome.
All unique 15-mer derived from protein sequences in these five
groups were included in the array in a single copy, except for a
random subset of peptides, which were replicated for technical var-
iability assessment (6549 peptides in two or more copies, 992 in five
or more copies). Peptide fields were distributed in 12 microarray
sectors of 18,700 peptides each. Peptides from the same protein
were synthesized at randomized positions within a single sector. The
chip contains additional 2386 unique peptides corresponding to eight
proteins not accounted within the protein groups defined above (and
of which 2 proteins resulted seropositive), including members of the
T. cruzi TASV protein family (30, 31) and 21 epitopes of high preva-
lence in healthy humans (not associated to Chagas disease, identified
in the IEDB with a search for linear B-cell epitopes from any source
with sero-prevalence   50%, assayed in at least 20 subjects). The
sequences of these 532 proteins (457 T. cruzi proteins, 54 neo-
proteins and the additional 21 short peptidic epitopes of high preva-
lence in healthy humans) are available in supplemental Table S4.
Derivatization of Synthesis Slides—Synthesis slides (Nexterion P)
for the photolithographic synthesis of peptide arrays were purchased
from Schott AG, Germany and derivatized with a 2% w/v linear
copolymer of N,N-dimethylacrylamide and aminoethyl methacrylate
(both from Sigma-Aldrich) mixed in a 20:1 w/w ratio before polymer-
ization for 2 h at room temperature in freshly degassed 0.1 M sodium
borate buffer, pH 8 containing 0.025% v/v TEMED and 0.1% w/v
ammonium persulfate (18).
Peptide Arrays Synthesis—Each peptide field was composed of
2  2 mirrors controlled by the Digital Micro-mirror Device, and with
a single-mirror border separation within fields. This setup allows
high-throughput while maintaining a high field resolution. The spacer
polypeptide DAPAD was added to all peptides at their C-terminal. The
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FLAG peptide DYKDDDDKK extended c-terminally with a linker pep-
tide (GAPAGAP) was included in the microarray in 852 copies for
peptide synthesis quality control and as corner (reference positions)
markers. Synthesis of the arrays was performed as described previ-
ously (18).
Human Sera Samples—
T. cruzi—infected human sera samples used in this study were
obtained from the Laboratorio de Enfermedad de Chagas, Hospital de
Nin˜os “Dr. Ricardo Gutierrez” (Buenos Aires, Argentina). All proce-
dures were approved by the institutional review board of this institu-
tion. Written informed consent was obtained from all individuals, and
all samples were decoded and de-identified before they were pro-
vided for research purposes. Sera were collected from clotted blood
obtained by venipuncture and analyzed for T. cruzi-specific antibod-
ies by commercially available kits: enzyme-linked immunosorbent
assay (ELISA) using total parasite homogenate (Wiener lab, Argentina)
and indirect hemagglutination (Polychaco, Buenos Aires, Argentina).
The negative panel was composed of 10 samples from healthy,
non-infected individuals that gave negative results in the mentioned
tests. Using these 10 samples, four different T. cruzi seronegative
sera pools were prepared by taking five random samples (3 l per
serum) in each case, and labeled them A_neg, B_neg, C_neg and
D_neg. In the case of Chagas-positive samples, we selected nine
samples from patients that had no clinical symptoms, and were clas-
sified in the Chagas chronic indeterminate stage (19). Using
these nine samples, four different T. cruzi seropositive sera pools
were prepared by taking five random samples (3 l per serum) in each
case, and labeled them A, B, C, and D. We used the smallest pool
size, which would cover most of the high prevalence antibody spec-
ificities. For this, we estimated that all epitopes of a prevalence of
50% or higher will be present at least in 1 individual serum with a
probability higher than 95%. Briefly, for an epitope of prevalence x in
the infected population, the probability of randomly taking n subjects
without specific antibodies, assuming independence is (1 - x)n. Then,
we calculated the minimum x, such that (1 - x)n  0.05 (i.e. that the
probability of not sampling an epitope of prevalence x% or higher in
n subjects is less than 0.05). Performing this calculation, we find n 
5, i.e. (1 - 0.5)5  0. IgGs were purified from 15 l sera pools using
Melon Gel IgG spin purification kit (Thermo Scientific), following the
manufacturer’s protocol. Purified IgG samples were checked in 12%
SDS-PAGE gels. IgG concentration was estimated after staining by
Coomassie Brilliant Blue, by comparison against a standard curve
made by electrophoresing different quantities of purified bovine
-globulin (IgG, 150 kDa, BioRad Laboratories, Hercules, CA).
Assays with Peptide Arrays and Data Acquisition—Microarray
slides were incubated essentially as described in (16) with a few
modifications to accommodate sequential incubations. Briefly, slides
were incubated at room temperature overnight with 1 ml of purified
pooled IgGs, diluted to 20 g/ml in 0.15 M Tris/Acetate pH 8.0, 0.1%
v/v Tween20. After washing with the incubation buffer, slides were
incubated for 2 h with secondary antibody (Cy3 goat anti-human IgG,
Abcam Cat. No. Ab97170) at 1 g/ml. After a second washing step
with incubation buffer, followed by air-drying of the slides in a nitro-
gen jet, the peptide array slides were scanned and recorded with an
Innoscan 900, Cambridge, MA laser scanner (INNOPSYS, Carbonne,
France) at 1 m resolution, with an excitation wavelength of 532 nm.
The images recorded with the laser scanner were analyzed using the
PepArray analysis program (Schafer-N, Copenhagen Denmark). Aux-
iliary “marker” peptides with sequence DYKDDDKKGAPAGAP con-
taining the FLAG epitope tag, were used for positioning of the grid
and to quantify spots’ intensities. For all microarray experiments
described, the same procedure was performed first with the negative
sample (from healthy subjects), and then sequentially with the positive
sample (from infected patients) in the same conditions. Therefore two
readouts were obtained per slide: the negative sample data and the
cumulative signal of negative and positive sample data. A total of 8
microarray chips were assayed, labeled A1 (Sample A_neg followed
by Sample A, Replicate 1), A2 (Sample A_neg followed by Sample A,
Replicate 2), A3 (Sample A_neg followed by Sample A, Replicate 3),
B1 (Sample B_neg followed by Sample B, Replicate 1), B2 (Sample
B_neg followed by Sample B, Replicate 2), C1 (Sample C_neg fol-
lowed by Sample C, Replicate 1), C2 (Sample C_neg followed by
Sample C, Replicate 2), and D1 (Sample D_neg followed by Sample
D, Replicate 1). Raw intensity data sets for each chip and sample are
available in public databases (See Data availability Section).
Peptide Mapping, Data Normalization, Signal Smoothing and Neg-
ative Subtraction—In previous successful applications of HD-peptide
microarrays (16, 18, 32, 33), minimal data normalization was per-
formed. However, unlike previous work, here we analyzed a complex
antibody sample and compared relative intensities across different
experiments. This demanded further normalization. A first normaliza-
tion step was implemented, aimed at equalizing two sequential reads
of a single chip (the negative and the cumulated negativepositive
data) and decreasing sector (spatial) effects across the chips. For this,
we defined an intensity baseline for each sector as its most frequent
intensity value (mode). Each peptide was then centered by subtract-
ing its associated baseline value. Once baseline signal was adjusted,
intensity dispersion across sequential reads of a single chip was
adjusted by dividing each value by the 90th percentile of the intensity
values of the 24,000 random peptides in the same assay, therefore
bringing the negative and negativepositive cumulated signals into a
common scale. Peptide sequences and their fluorescence values
were mapped back to the parental proteins sequences (only allowing
a perfect sequence match of the 15 residues). The plots display
intensity values for individual peptides along the protein sequence
(i.e. from position 1, to protein length minus 14). We devised a simple
smoothing procedure to improve the signal to noise ratio of individual
measurements. Smoothing was performed on each protein profile,
and consisted in a running median filter of window length 5, followed
by a running mean filter of window length 7. Basically, the normalized
signal of the peptide at position i in the parental protein sequence is
first replaced by the median value calculated from the five peptides at
positions i - 2 to i 2. In a second run, after extreme values had been
removed, the value of the peptide at position i in the parental protein
sequence is now replaced by the mean value calculated from the
seven peptides at positions i - 3 to i  3. When reaching the C-ter-
minal end, we padded the window length with zeroes to complete the
scan. Epitope mapping performance (average AUC, as presented in
Results), was incremented by5% after signal smoothing. Smoothed
negative sample signal was subtracted from smoothed cumulated
negativepositive signal to obtain a smoothed Chagas specific anti-
body-binding signal, which was plotted as shown in Fig. 1. In many
proteins, such as the Ribosomal protein L19 and antigen CA-2/B13 in
Fig. 1, a repetitive signal pattern is produced by tandemly repeated
(antigenic) amino acid motifs in those protein sequences. Because in
each microarray experiment we obtain a single reactivity value for
each distinct peptide, if the same peptide has to be mapped to
different places in a protein sequence, its associated value would also
be repeated, therefore producing such a regular signal pattern. In
many cases some of these repeats are not strictly conserved, be-
cause of sequence polymorphisms (they are imperfect repeats, but
still recognizable as repeat units). This creates an irregular or imper-
fect repetitive signal pattern for some proteins, usually at the borders
of the tandemly repeated motifs. To compare intensity values from
different chips and biological samples, an additional step was re-
quired to compensate for chip-to-chip intensity distribution dispari-
ties. In this case, quantile normalization (34) was performed to force
the 3 signal distributions (pre-normalized and smoothed intensity
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values of negative samples, negative  positive samples and sub-
tracted signals) to be the same across chips/samples. This was done
independently for the negative, cumulative and subtracted data sets,
using the R package preprocessCore (34). The three normalized data
sets obtained for each chip after this transformation were used for all
subsequent analysis and figures shown in this paper (distributions are
shown in supplemental Fig. S3). In the subtracted signal distribution,
1 unit is approximately equivalent to the 95th percentile. The normal-
ized and smoothed values from a total of 8 chips assayed (see above)
are publicly available (refer to “Data Availability” section).
Epitope Mapping Performance Analysis—For this analysis, we
compiled a validation data set of antigens with B-cell epitope map-
ping data, that met the following criteria: (1) had specific reactivity
against chronic T. cruzi infected human sera; (2) the mapped epitopes
had been reported in at least 2 independent publications; (3) were
able to discriminate T. cruzi seropositive and seronegative humans in
ELISA format using synthetic peptides. From an initial data set of 24
proteins with mapped B-cell epitopes, only nine remained that met
this criteria, after removing paralogs and redundant epitopes (peptide
sequences and references are listed in supplemental Table S3, col-
umn F “High-confidence mapped B-cell Linear Epitopes”). In each
antigen sequence, we mapped the exact location of the reported
epitope onto the parental sequence. In the case of reported epitopes
of length5 residues, we split the original epitope into smaller “units”
of length 5. This extension of the epitope definition was especially
relevant in the case of repetitive antigens, where the presence of
cross-reactive degenerate repeats (with minor amino acid substitu-
tions) is frequent. Then, we classified as “positive” every 15-mer
peptide containing any of these epitopes, and as ‘negative’ the re-
maining peptides. Receiver operating characteristic (ROC)1 analyses
were performed for each protein, to assess whether higher chip
intensities were associated with epitope localizations. The area under
the ROC curve (AUC) was measured for each antigen using the R
package ROCR (35). Redundant peptides (identical 15-mers) were
excluded from the analysis. The supplemental Fig. S1 shows ROC
curves, AUC values, and sensitivities and specificities versus cut-off,
for each of these 9 antigens, considering individual sera samples or
their average. To assess the performance of combined data from
different experiments, the normalized and negative sample-sub-
tracted peptides values of different chip/assays were averaged and
ROC analysis performed as described.
Sensitivity, Positive Predictive Value, and Cut-Off Definition—The
cut-off used to define “positive” and “negative” peptide reactivity was
set to maximize classification performance measures of sensitivity
(true positives/(true positives  false negatives)) and positive pre-
dicted values (PPV  true positives/(true positives  false positives)).
Positive predictive value is used in this paper in the context of binary
classification of antigens and non-antigens, equivalently to classifi-
cation precision; it should not be confused with classification of
subjects based on infection status as frequently used in diagnosis.
The validation set of 9 antigens with mapped linear B-cell epitopes of
high confidence (Epitopes listed in supplemental Table S3, column F
“High-confidence mapped B-cell Linear Epitopes”) was used as true
positive (i.e. if classification is perfect, these proteins should contain
highly reactive peptides and hence be classified as ‘positives’ pro-
teins). The set of 54 neo-proteins (Group 5) was used as negative
controls (i.e. if classification is perfect, these ‘proteins’ should not
contain highly reactive peptides and hence be classified as negative
proteins). For this task, the averaged normalized signal from the 8
chips was used. As observed in Fig. 4C, it is clear that in the cut-off
range around 3 (from 2.6 to 3.4) all positive controls (validated
epitopes; dark blue curve) are detected but no negative controls are
(random sequences; black curve), i.e. both sensitivity/recall and PPV/
precision are optimal in this interval. Therefore, a cut-off of 3 was
chosen for the averaged signal. Conducting the same analysis on
individual samples required a higher cut-off to maintain a PPV of
100% at the expense of sensitivity. In this case, a threshold of seven
resulted in a PPV of 100% in all samples and a sensitivity of 0.83 	
0.11, illustrating the previously described variation between different
biological samples.
Definition of Antigenic Regions—For simplification, any continuous
protein sequence range where all its peptide reactivities were above
the cut-off (average signal  3) was defined as an antigenic region.
These are shown in supplemental Table S2. Here, we have also
included a list of non-redundant antigenic regions (Sheet 2,
“unique15mers”) by removing those regions that are identical, in
terms of the sequence of their most reactive 15-mer peptides (Max
pep sequence in supplemental Table S2), to other regions of higher
ranks (according to seroreactivity). Finally, an additional filter was
applied to remove related antigenic regions (Sheet 3, “unique7mers”).
Here, an antigenic region was removed if its most reactive 15-mer had
an internal 7-mer sub-sequence matching the most reactive 15-mer
of an antigenic region of higher rank.
Analysis of Technical Reproducibility and Biological Variability—
Variability between identical peptides was assessed from 992 differ-
ent peptide sequences (a random sample) that were each replicated
in at least 5 random positions in the microarray (and up to 25 repli-
cates per peptide). Coefficients of variation associated to these pep-
tides (raw values, ranging from 0 to 255) were calculated per chip, as
the standard deviation of intensity divided by mean intensity. Mean
intensities were corrected by adding one, to avoid divisions by zero.
Because the length of most continuous B-cell epitopes is less than
the length of the synthesized peptides, antibody-binding signals are
expected to be shared among multiple overlapped peptides (i.e.
among adjacent peptides covering a common antigenic determinant).
The intensity correlation between all pairs of peptides derived from
the same protein (but physically located at random microarray posi-
tions) was high for highly overlapped peptides (PCC of 0.86 	 0.02
(S.D.), 14 residue overlap, i.e. with single residue shifts) and mono-
tonically decreases for lower sequence overlaps (down to a PCC
0.25 for pairs of peptides with a six residue overlap). This analysis
was performed with a subset of 105 reactive and nonrepetitive pro-
teins (i.e. excluding those proteins where 20% of sequence is
composed of internal tandem repeats, as detected by the TRUST
repeat detection method (36)).
To assess technical variability across chips, PCC were calculated
for all pairs of chips assayed with the same sample (three pairs of
sample A replicates, one of sample B replicates and one of sample C
replicates). In this case, the signal correlation for the same peptide
across different chips, was calculated from normalized and smoothed
intensity values of199,000 unique peptides. Correlations of peptide
intensities between chips assayed with different samples (biological
replicates) were calculated in the same way. In addition, protein-wise
inter-sample comparisons were performed. First, each protein was
assigned a reactivity value equal to the normalized value of its most
reactive peptide. Then, we calculated for each pair of samples, the
fraction of proteins that passed the reactivity signal cut-off (a value of
seven was previously defined for individual samples) in any of the two
samples (S1 OR S2) or in the two samples simultaneously (S1 AND
S2). The proportion of shared positive proteins between two samples
was calculated as (S1 AND S2)/(S1 OR S2). This is illustrated in the
scatterplot in Fig. 2C.
1 The abbreviations used are: HD-Chips, high-density peptide
chips; ROC, Receiver Operating Characteristic; AUC, Area under the
ROC curve; PPV, Positive-Predictive Value; PCC, Pearson product-
moment Correlation Coefficient.
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ELISA Validation of TSSA Antigen—The Gluthatione S-transferase
(GST)-fusion protein bearing the central and antigenic region of CL
Brener TSSA (GST-TSSA-CL) has been described (22). GST-
TSSA-CL deletion variants spanning the 15-mer peptides covering
the antigen in region of TSSA with offset of six residues (equivalent to
peptide-to-peptide overlap of nine residues) were constructed by
fill-in of partially complementary forward and reverse oligonucleotides
(supplemental Table S5) containing BamHI and EcoRI sites on their 5
ends, respectively. All of these constructs were treated with restric-
tion enzymes and cloned using the BamHI and EcoRI sites of the
pGEX1T vector (GE Healthcare). Colony-PCR was used for the initial
screening of the colonies, which were subsequently confirmed using
Sanger-based sequencing. GST-fusion molecules were expressed,
purified and quantified as previously described (22). Each GST-
TSSA-CL deletion variant (plus a GST and GST-TSSA-CL negative
and positive control, respectively) was tested against individual hu-
man serum (nine T. cruzi positive and three T. cruzi negative samples,
as described in Human Sera Samples section) by ELISA as described
elsewhere (37). The seroprevalence of each peptide was calculated as
the proportion of individual sera samples with mean absorbance
above the cut-off (n  9). ELISA 
 O.D. (absorbance) in reactive
samples, the quantity plotted in Fig. 3 - right axis was calculated for
each peptide, as the mean O.D. (3 replicates average) detected in T.
cruzi positive samples (only if measured OD is above ELISA cut-off),
minus the average O.D. measured in negative control samples.
Agreement of ELISA versus chip data was evaluated by Spearman’s
rank correlation (r  1, p  0.017) of normalized and subtracted chip
data versus average absorbance of the nine positive samples, after
subtracting average absorbance of three negative sera samples  5
standard deviations.
Data Availability—The array design and raw and processed array
data have been deposited in the ArrayExpress database at the Euro-
pean Bioinformatics Institute under accession numbers A-MTAB-526
and E-MTAB-3008, respectively. The complete set of peptides was
also submitted to the Immune Epitope Database Resource (5) under
submission ID 1000642.
RESULTS
Design of a High-density Peptide Chip for Screening and
Mapping B-cell Epitopes in Chagas Disease—We designed a
high-density peptide chip layout containing 225,200 address-
able spots, displaying 199,643 unique 15-mer peptides.
These peptides were derived from 381 serologically unchar-
acterized protein sequences derived from the T. cruzi pro-
teome, along with 68 T. cruzi protein sequences from antigens
with previous serological evidence in infected humans (from
weak evidence in some cases to very strong evidence includ-
ing epitope mapping in others), and 54 neo-proteins of ran-
dom sequence as a negative set used to define the signal
baseline in all experiments (see Experimental Procedures for
details). In all cases, each complete protein was scanned with
a tiling collection of 15-mer peptides overlapped by 14 resi-
dues, i.e. with an offset of one residue, to achieve maximum
resolution. Next, we selected serum samples from Chagas
Disease patients or healthy donors, with positive or negative
serology for T. cruzi, respectively, using routine diagnostic
methods, and assayed each chip successively with negative
and positive pooled samples, therefore producing two fluo-
rescence readouts. After signal processing and normalization
(described below), the subtraction of the negative signal from
the final readout produced an informative, disease-specific
signal that was characterized further. Negative signal subtrac-
tion produced a significant improvement on the epitope map-
ping performance, see later. We then used the normalized
signal for each addressable field in the chip to reconstruct the
antibody binding profile for each protein.
A number of artifacts may distort the signal in microarray
experiments. To correct for these random distortions, we
applied a fast, robust, and simple smoothing procedure on
these protein signal profiles. This procedure is based on the
knowledge that most linear epitopes are 5–7 residues long
(38). Because any two peptides in the array share a 14aa
overlap, we expect that specific antibodies will bind several
consecutive 15-mers. By using a smoothing procedure based
on combined mean and median values in two sliding windows
along the reconstructed protein profiles, we removed outliers
and other noisy data points while still capturing the important
signal patterns in the data. We also applied a global normal-
ization procedure to the data to compare intensity values from
different chip experiments and/or multiple readouts in suc-
cessive assays with a single chip. This procedure allowed us
to scale values of each individual chip, and each internal
sector within a chip (see Experimental Procedures for details).
Signal smoothing, signal normalization, and nonspecific sig-
nal subtraction all contributed with an increment in epitope
mapping performance.
Performance of the HD-Chip Platform: Mapping of Known
Chagas Disease Epitopes—We first benchmarked the ability
of HD-Chips to fine map and identify a set of previously
characterized B-cell epitopes associated with human T. cruzi
chronic infections. As described above, each peptide chip
was assayed sequentially, first with a pool of negative anti-
body samples (IgGs purified from five individual sera), fol-
lowed by a pool of Chagas-positive antibody samples (IgGs
purified from five individual T. cruzi positive sera). The bench-
mark consisted in correlating residue by residue the chip
signal with the location of high confidence B-cell epitopes in
nine validated antigens (shown in supplemental Table S3. An
excellent epitope mapping performance was obtained, with a
mean area under the ROC curve (AUC) for these antigens of
0.964 in the single best performing assay, and with a global
average AUC of 0.912 	 0.054, obtained by averaging the
AUC measured for these antigens in all chip replicates (using
4 different sera pools, labeled A, B, C, and D, see Experimen-
tal Procedures). Fig. 1A shows examples of the antigenicity
profiles obtained for three of the validated antigens together
with the location of previously known B-cell epitopes and their
corresponding AUC performance measures. Fig. 1B, summa-
rizes the epitope mapping performance in all the 9 validated
antigens. Reactivity data obtained from the negative samples
(in magenta in Fig. 1) have zero epitope mapping capacity,
with a mean AUC centered around 0.5, whereas data from the
positive samples show an excellent performance with a mean
AUC close to 1 (Fig. 1 in gray or green, signals before or after
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negative-signal subtraction, respectively). Epitope mapping
performance was significantly improved by subtraction of
negative signal. Antigens’ AUC values were significantly in-
cremented after negative signal subtraction, from an average
AUC of 0.948 before subtraction to an average AUC of 0.972
after subtraction (p  0.05, paired Wilcoxon signed rank, n 
9). supplemental Fig. S1 shows the antigenicity profiles of all
known Chagas antigens with their validated epitopes, as
measured with each biological sample (A, B, C, and D) and
their average across all experiments.
High Technical Reproducibility Expedites Studies on the
Diversity of B-Cell Responses Using HD-Chips—We next as-
sessed the technical reproducibility of HD-Chips. For this, we
analyzed the signal of identical peptides replicated at random
locations on the chip (992 different peptide sequences, rang-
ing from five to 25 copies each). These showed consistent
intensities, with a mean coefficient of variation (i.e. standard
deviation/mean) of 0.19 (	 0.05, in 8 replicates using four
different biological samples). We then analyzed and com-
pared the signal obtained from chips produced and assayed
with the same biological samples (technical replicates). These
showed a very high reproducibility, with peptide normalized
values (n 199,000) across technical replicates showing a
Pearson Coefficient Correlation (PCC) of 0.9	 0.032 (over the
five different technical replicates described under “Experi-
mental Procedures”, see Fig. 2A).
Given this high technical reproducibility, we proceeded to
compare the antibody-binding signals across different biolog-
ical samples. As expected, when comparing complete chip
data assayed with purified IgGs from different sera pools, a
much larger variability was observed. As shown in Fig. 2B for
two pools, only a subset of peptides were reactive in both
samples, and many peptides were reactive against one of the
samples but not the other (with an overall correlation (PCC) of
FIG. 1. Epitope Mapping Performance using a single peptide microarray. A, Protein Antigenicity profiles of three validated T. cruzi
antigens: CA-2/B13, 60 S Ribosomal protein P2 and Ribosomal Protein L19. Horizontal axes show the amino acid positions of the protein
sequences; vertical axes show the smoothed and normalized mean intensity values from a single peptide chip (sera pool C, replicate 1). In
magenta: signal from negative sample (N). In black: cumulative signal from the negative and positive sample (NP). In green: Chagas-specific
signal (subtraction of NP-N). Blue marks near the baseline show the position of known B-cell epitopes (antigenic regions within these antigens),
as reported in the literature. B, Density plots showing the distribution of area under the ROC curve (AUC) values, where AUC 1 means perfect
residue by residue correspondence of signal with localization of previous known epitopes for 9 validation antigens. Color code for samples is
the same as for panel A. Magenta: AUCs centered on 0.5, meaning no predictive performance. Black: average AUC  0.861, for cumulative
negative  positive signal. Green: AUC  0.96, corresponding to Chagas-specific signal (for the single best performing assay).
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0.558 	 0.138, over the six different combinations of biolog-
ical samples described under “Experimental Procedures”).
When we considered the antibody-binding reactivity at the
level of full-length proteins, by assigning to each protein a
single score corresponding to the peptide with the highest
signal within the protein sequence, a similar pattern of diver-
sity was observed. Two sera pools shared on average 52% 	
10.6% of the positive antigens (Fig. 2C; serologically positive
was defined above a threshold explained in the next section).
When comparing antibody specificities from different pos-
itive sera pools, it was expected that the pool-to-pool vari-
ability would decrease when increasing the size of those pools
(i.e. effectively assaying a larger number of sera). Indeed, by
adding signals from HD-Chips assayed with two sera pools
into a larger virtual pool, two pools shared up to 70% of the
positives antigens (Fig. 2D). Moreover, combination of data
from different pools also increased the disease-specific signal
allowing better separation of antigens from non-antigens. This
FIG. 2. Technical reproducibility and biological variability. On the left, scatterplots of normalized peptide reactivity values of (A): 2
technical replicates assayed with sample A (Pearson’s correlation coefficient, PCC 0.93), and (B) two different biological samples (sera pools
A and B, PCC  0.54). On the right, normalized peptide reactivities were grouped by source protein to calculate protein-wise reactivities, as
described under “Experimental Procedures.” In these scatterplots of protein reactivities, biological variability between sera pools at the level
of proteins can be observed. In panel C, signals from 2 individual sera pools/chip assays were compared, whereas in panel D, signals from
pairs of pools were averaged before plotting. Green points represent query proteins, black points the randomly generated sequences and blue
points, antigens with previously validated epitopes. Vertical and horizontal lines, mark the cut-off, calculated as described under “Experimental
Procedures.” Using this cut-off, Sample A and B share 44% of reactive proteins (panel C), and the averaged signal from the two sera pools
(labeled A and C) share 70% of reactive proteins with the averaged signal from two other pools (labeled B and D, panel D).
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can be seen in Fig. 2D, where positive controls (blue points)
are clearly separated from the negative controls (black
points). As shown in Fig. 2C, the relative signal for each
antigen is not fully conserved across chip replicates assayed
with separate biological samples. Every sample provided ad-
ditional antigenicity information, and combining signal from
two or more biological replicates led to an increased perfor-
mance for mapping known epitopes. When considering pairs
of chips assayed with different biological samples (using their
averaged signal), we observed an increment of 6% in the
AUCs (from a mean of 0.912 to a mean of 0.964). Moreover,
the epitope mapping performance was further improved by
increasing the number of biological replicates to three (aver-
aging the signal from three assays with different pools of sera)
to a mean AUC of 0.972. Adding a fourth biological replica,
did not lead to further increases in the AUC value (data not
shown). In contrast, technical replicates (averaging signal
from two chips assayed with identical biological samples)
produced only a small increment (0.6% AUC increment on
average) in epitope mapping performance.
High Resolution Mapping of Reactive Epitopes—When an-
alyzing the epitope mapping performance for previously de-
scribed antigens, we noticed a unique case that displayed a
highly antigenic region that did not agree perfectly with the
previously described epitopes. This antigen, the Trypomas-
tigote Small Surface Antigen (TSSA), is used for serological
discrimination of T. cruzi lineages (39, 40). Di Noia et al.
performed a preliminary epitope mapping of the TSSA protein
identifying one major epitope (41-KPATGEAPSQ-50) along
with two minor (weak signal and low prevalence) epitopes
(30-TSSTPPSGTEN-41 and 36-SGTENKPATG-45) (39). This
study was carried out with a limited number of short peptides
of varying lengths (8–11 residues), and with a relatively large
offset (five residues) for some key peptides. Here, we scanned
the full-length of the TSSA protein at maximal resolution (one
residue offset), detecting a single, broad antigenic region
spanning residues 24 to 57, with a maximum signal located
between residues 30 and 46 (see Fig. 3). So although the
location of the identified central antigenic region agrees be-
tween the two studies, the location of the peak of the anti-
genic signal differs. To further investigate this discrepancy
and further study the seroprevalence of individual responses
to TSSA peptides, we re-assayed five overlapping peptides
from this antigenic region in an ELISA format assay using 9
individual (not pooled) human sera samples. Data from the
peptide chip and from the ELISA assays are provided in
supplemental Table S1. The antigenicity profile of the TSSA
antigen, as obtained from the HD-Chips is depicted in Fig. 3
along with the signal from the five individual peptides (P24–
38, P30–44, P36–50, P42–56, and P48–62) assayed in ELISA
format. The correlation of both seroprevalence (fraction of the
nine donors that responded to each peptides) and seroreac-
FIG. 3. Antigenicity profile of the TSSA antigen and ELISA validation of HD-Chip data. x-axis represents each 15-mer peptide
(from 1–15 to 78–92) and y-axis is the averaged normalized and subtracted signal from 8 chip replicates. Five peptides (P24–38, P30–44,
P36–50, P42–56 and P48–62) were individually tested against 9 T. cruzi positive human sera samples in ELISA format. Red crosses depict
seroprevalence of these peptides, ranging from 0% (P24.38 and P48–62) to 89% (P39–44, 8 of 9). Green bars represent full range of ELISA
reactivity of these five peptides across different seropositive subjects (absorbance increment above negative controls. Middle mark is the
average value). Horizontal bars at the bottom represent the major (E1, blue, from residue 41 to 50) and minor low-reactivity epitopes
(light blue: E2, from 30 to 41, and E3, from 36 to 45) as reported previously (42). These bars are placed to cover all 15mer peptides
containing the full epitope sequence (for example, E2 is colored by four peptides starting in positions 27–30). Horizontal black bar and
triangle in the bottom represent signal peptide and glycophosphatidylinositol anchor cleave site respectively (protein regions absent in its
mature form).
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tivity (average ELISA signal of each the positive individual
donors to each peptide) with the chip intensity values is
evident, strongly suggesting that the dominant TSSA epitope
is located in the region P30–46, and not in the region P41–50
as reported previously. This example shows the high accu-
racy of HD-Chips to map linear epitopes, which can be ex-
ploited to refine previous epitopes where mapping might be
imprecise because of technological or cost issues resulting in
poor mapping resolution (insufficient number of peptides, or
low peptide overlap).
Discovery and Fine Mapping of Novel Antigenic Determi-
nants—We next applied these HD-Chips to the identification
of novel antigens and antigenic determinants (new candidate
diagnostic markers). For this, we analyzed the seroreactivity
of 175,566 distinct 15-mer peptides, covering 457 proteins at
maximum resolution from the T. cruzi CL-Brener proteome.
These peptides cover 3% of the 6.3 million 15-mer unique
peptides of this proteome. Protein sets were defined as fol-
lows (for details see the section on “Experimental Proce-
dures”): Group 1: 50 proteins randomly selected from the
proteome (serologically uncharacterized); Group 2: 99 pro-
teins prioritized by a multi-feature integrative bioinformatics
strategy (25) (serologically uncharacterized); Group 3: 232
serologically uncharacterized members of the MASP family of
surface proteins (41); Group 4: 68 proteins with previous
evidence of seroreactivity in T. cruzi infected humans (both
with and without previously mapped epitopes). As mentioned
(see “Experimental Procedures”), we also included 54 neo-
proteins of random sequence (Group 5) to measure the back-
ground distribution of antibody-binding signal in the chips,
and 8 additional parasite proteins not belonging to any of the
other groups. Peptides included in this HD-Chagas-Chip de-
sign were derived from proteins in all these groups by taking
all possible 15-mer subsequences.
To establish a reactivity threshold to classify proteins and
peptides as ‘positive’ (reactive) or ‘negative’ (not reactive), we
analyzed the sensitivity for each protein group (fraction of
identified proteins) as a function of decreasing chip-signal
score. In this analysis, each protein was assigned a single
score corresponding to the peptide with the highest signal
within the protein sequence. The analysis included 8 repli-
cates for each protein sequence (one from each of the eight-
chip assays performed). The signal from each chip was pro-
cessed as described earlier to reduce noise and allow for
standardization between chips, and the final signal reported is
the average over the 8 replicates.
Using these data, we generated an antigenicity profile for
each protein (like the ones depicted in Fig. 1). Next, we sorted
from high to low these profiles on overall antigenicity score
(signal from the highest scoring peptide contained within the
given protein). The result of this analysis is shown in Fig. 4
(panels A and B). From this figure, separation of the positive
controls (the 9 antigens with high-confidence epitopes) from
the negative controls (random neo-proteins) is evident,
whereas the serologically uncharacterized proteins were dis-
tributed along the full reactivity range. Using a reactivity
threshold of 3 (Fig. 4C) we can identify all positive controls
(100% sensitivity) and no negative controls, corresponding to
a specificity and predicted positive value (PPV) of 100%
(equivalent to 0% false positives). Applying this cut-off to the
complete data set, we detected 2031 Chagas-specific posi-
tive peptides in 122 distinct proteins.
Using this threshold, around 1% of all peptides were hence
found positive with substantial positivity rate differences
across protein groups. Group 4 had the highest positivity rate
with2.62% of its peptides being positive, followed by Group
3 of MASP family proteins with 1.21% of positive peptides,
followed by Group 2 containing peptides from prioritized pro-
teins with a rate of 0.84%; and finally Group 1 (randomly
selected proteins) with a 0.13% rate. Noteworthy, our integra-
tive multi-feature prioritization strategy (25) produced a six-
fold increment in the peptide reactivity rate compared with
selecting proteins at random (group 2 versus group 1). De-
tailed reactivity rates for each protein group are summarized
in Table I, and protein profiles for all positive proteins are
shown in supplemental Fig. S2.
Next, to further delineate antigenic portions of the analyzed
proteins we defined any group of consecutive reactive pep-
tides located in a specific region of an antigen as an ‘antigenic
region’ (see “Experimental Procedures”). These regions are
defined by peaks in the antibody-binding signal observed
from the arrays and contain one or more B-cell epitopes. The
2031 positive peptides detected were mapped to 187 distinct
antigenic regions. After removal of peptides from known T.
cruzi antigens, the remaining 1164 peptides (121 unique re-
gions, which map to 97 novel T. cruzi antigens), represent new
peptidic markers for Chagas Disease, for which this report
represents their first serological characterization. Further-
more, from the 24 positive proteins with prior serologic evi-
dence (Group 4), we detected new antigenic regions (not
reported previously) in 10 of them (shown in supplemental
Table S2). Protein reactivity rates for each protein group are
summarized in Table II. Briefly, 35% of proteins in Group 4
were Positive, followed by a 30% of Group 3 (MASPs), fol-
lowed by a 21% of prioritized protein (Group 2) and a 10% of
randomly picked proteins (Group 1).
In summary, our study is providing detailed information on
the linear antigenic determinants for both novel antigens, and
for a subset of antigens that have not been characterized in
detail until now. A table with all antigenic regions along with
their source protein, localization, sequence and reactivity data
is available as supplemental Table S2.
It is worth mentioning that prior to this work, the number of
known T. cruzi antigens recognized from human infections was
68, and the number of those with mapped epitopes were 20
(see supplemental Table S3). Therefore, despite the fact that our
HD-Chip contained a still low representation of the T. cruzi
proteome (3% of the proteome was displayed in our design),
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we were able to increase the coverage of known antigens for
this pathogen more than twofold, and more than 10-fold in the
case of finely mapped antigenic regions, essentially providing
the majority of currently known epitopes for this disease.
DISCUSSION
This study provides so far the largest number of fine anti-
body specificities simultaneously measured for a human infec-
tion, with more than a 10-fold increment in throughput when
compared with previous screenings using peptide microarrays
(7, 13, 42, 43). With only 20 g of purified immunoglobulin
directly obtained from human clinical samples, these high-den-
sity peptide microarrays allowed the recognition of specificities
against 180,000 distinct pathogen-specific 15-mer peptides.
Moreover, a sequential incubation protocol allowed subtraction
of signal from healthy/non-infected human samples to obtain
infection-specific signal in each microarray slide.
We benchmarked the precision of our measurements us-
ing previously known antigens with mapped B-cell linear
epitopes. These experiments showed that HD-Chips have an
FIG. 4. Global visualization of antigen and epitope discovery. A, Concatenation of all protein profiles (similar to those in Fig. 1) ordered
from left to right according to the peptide with the highest signal in each protein. The x axis shows the residue position for all concate-
nated proteins (full length including their antigenic and non-reactive regions), and the y axis represents the averaged, normalized and
subtracted reactivity values (Chagas-specific signal). B, Enlarged region showing the antigenicity profiles of proteins that lie to the left of the
selected threshold value of 3 (colored vertical line). Horizontal boxes intercalated below the concatenated profiles represent individual proteins.
Blue boxes represent antigens with previously validated linear epitopes. Cyan boxes are proteins with previous serology evidence (Protein
Group 4) but without known linear epitopes. Black boxes correspond to random sequences (Group 5). Green boxes represent serologically
uncharacterized (‘query’) T. cruzi proteins (Groups 1, 2 and 3). C, Enrichment of different groups of proteins along the ranking. Bottom x-axis:
antigenicity rank, with the most antigenic protein (according to the highest scoring peptide) at the left. Top x-axis: protein antigenicity score.
In the y-axis, the cumulated fraction of proteins at each ranking position, for the different protein group.
TABLE I
Chagas-specific positivity rates in different peptide sets. The table shows the total number of distinct peptides assayed in each group; the
number of positive peptides (above cutoff of 3) in the averaged signal (combining data from eight peptide-chip assays); the average number of
positive peptides in a single experiment (single chip/single sample above cut-off of 7); and the number of peptides that were positive in at least
1 out of the 4 sera samples (pools) tested. Percentages are given in parentheses. Group 5 of 24,000 randomly generated peptides (negative
control) had no positives in any case
Protein Set Description No. of Peptides
Positive Peptides
Average signal in all chips In single chip
Group 1 Proteins picked randomly from the proteome 38,664 50 (0.13%) 23.5 	 17.2
Group 2 Proteins ranked with a bioinformatics method 37,773 317 (0.84%) 133.25 	 38.54
Group 3 Proteins from MASP family 65,808 797 (1.21%) 399.75 	 219.3
Group 4 Proteins with previous seroreactivity evidence 32,372 848 (2.62%) 484.75 	 76.3
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excellent epitope mapping performance, with AUCs values
0.96 in a single microarray and an average AUC of 0.972
after combining data from multiple samples. Further analysis
showed that the deviation from a perfect AUC of 1 was only
because of single-residue differences at the boundaries of the
previously reported B-cell epitopes, particularly in the case of
antigens with multiple repetitive epitopes. An independent
validation in ELISA format of the TSSA antigen profile further
supported the mapping precision of HD-Chips. In fact, we
showed in this case that the major linear epitope within this
antigen is located between residues 30 and 46 and not be-
tween residues 41 to 50 as detected using a less accurate
technique (39).
The set of 15-mer peptides derived from randomly gener-
ated protein sequences was essential to define a nonspecific
antibody-binding baseline distribution, and to normalize the
data, allowing the subtraction of signal from incubations with
negative samples, and bringing the data from different mi-
croarray replicates into a common scale. These data was also
used to guide the selection of a reasonable threshold for
classification of reactive peptides. Using this threshold, more
than 2000 peptides, i.e. 1% of all screened 15-mer pep-
tides, resulted seropositive in T. cruzi infected human sera
pools and negative in the non-infected sera pools, with virtu-
ally no false positives (with the reactivity of all 24,000 ran-
domly generated peptides below the cut-off). Although this
threshold was defined based on the comparison against the
reactivity of random peptides, it is already well established
that both combinatorial libraries in phages (1), or random
peptides in high-density arrays (43, 44) can detect significant
and reproducible binding by mimicking natural epitopes.
Therefore, although we chose a very conservative threshold to
identify the most reactive peptides, lowering this threshold
can certainly provide additional Chagas-specific biomarkers.
In our benchmark, epitope mapping performance was en-
hanced by subtracting reactivity signals measured in healthy
donor samples, i.e. not related to the infection of interest, and
perhaps caused by exposure of patients to other infectious
agents or antigens with cross-reacting epitopes. Moreover,
with this experimental setup the two samples were compared
on the same physical spots, hence reducing the number of
required chips by half and suppressing the variability associ-
ated with peptide synthesis and slide manipulation.
Based on the presented evidence it is clear that these
HD-Chips are highly suitable for exhaustive mapping of the
specificities of B-cell responses against human pathogens.
Interestingly, antibody-binding to specific pathogen protein
regions was also detected when using sera pools from healthy
individuals (see for example the N-terminal region of the Ri-
bosomal protein L19 in Fig. 1A, additional cases are also
evident in supplemental Fig. S2). These antigenic determi-
nants may be shared with other pathogens to which the donor
has been exposed, or may represent cross-reactive determi-
nants to other antigens (perhaps from vaccination antigens).
In any case, the high-resolution scanning of antibody-binding
across the full length of proteins is able to precisely map these
regions, providing essential information for improving the
specificity of recombinant antigens used in diagnostic
applications.
In this context, it is interesting to compare the overall rate of
antigen discovery provided by peptide and whole-protein ar-
rays. Previous studies have profiled humoral immune re-
sponses in infected humans compared with healthy individu-
als for several pathogens using protein microarrays (45).
Some of the largest studies were performed for Mycobacte-
rium tuberculosis (4000 proteins, representing almost the
full proteome; with a 10% of seroreactive proteins) (8), Lep-
tospira interrogans (3300 proteins, representing almost full
proteome; with 5% of seroreactive proteins) (46), Brucella
melitensis (3000 proteins, representing almost full pro-
teome, with a 4% of seroreactive proteins) (47), and Plas-
modium falciparum (1200 proteins or 23% of its pro-
teome, with 13% of seroreactive proteins) (9). In our
experiments we obtained a1% global peptide positivity rate
(2,031 positive out of 175,566 unique T. cruzi derived 15-
mer peptides) when averaging signal from all HD-Chip exper-
iments. This rate, goes down to 0.5% if we consider a
non-redundant set of proteins with no prior serological char-
acterization. In terms of full-length proteins, this corresponds
to a 15% of the parasite proteins being targeted by the
humoral immune response in infected subjects. Despite the
fact that peptide microarrays are limited to identify linear
TABLE II
Chagas-specific positivity rates in different protein sets. The table shows the total number of distinct proteins assayed; the number of proteins
with any specific signal peak above the specified cutoff considering the averaged signal (combining data from eight peptide-chip assays); the
average number of positive proteins in a single experiment (single chipsample); and the number of proteins that displayed a positive signal
(above cutoff) in any of the four sera samples tested. Percentages are given in parentheses. Group 5 of randomly generated 54 neo proteins
(negative controls) had no positives in any case
Protein Set Description Number
Positive Proteins
Average signal in all chips In a single chip
Group 1 Proteins picked randomly from the proteome 50 5 (10%) 3 	 2.1
Group 2 Proteins ranked with a bioinformatics method 99 21 (21.21%) 10 	 1.4
Group 3 Proteins from MASP family 232 70 (30.17%) 46.25 	 11.6
Group 4 Proteins with previous seroreactivity evidence 68 24 (35.29%) 16.5 	 2.9
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epitopes, the estimated proportion of seroreactive proteins
observed here for Chagas Disease is in line and even above
those described in the aforementioned screenings using
whole protein microarrays in other pathogens.
Therefore, we believe that high-density peptide microarrays
offer an excellent platform for whole proteome screenings. In
scenarios where the peptide space to screen is still too large,
a combination of high-coverage whole-protein arrays fol-
lowed by a detailed epitope scanning using high-density pep-
tide chips could provide an excellent strategy to analyze
antibody responses against pathogens. In this strategy, pro-
tein arrays would streamline the process of antigen identifi-
cation, and HD peptide chips would precisely map the anti-
genic determinants in these antigens.
Besides the obvious practical impact of these large scale
antigen screenings on the development of improved serodi-
agnostics and vaccines, unbiased and exhaustive studies of
humoral immune response specificities in human infectious
diseases are needed for a better understanding of pathogen
immunogenicity and immunodominance, and to improve cur-
rent antigenicity prediction tools (48, 49). In our study, we
successfully detected all antigenic determinants in high-con-
fidence antigens with mapped B-cell epitopes. We were also
able to discover and map the locations of epitopes for previ-
ously described antigens that lacked detailed B-cell epitope
mappings. However, we failed to detect linear antigenic de-
terminants for some of the proteins with previous serological
evidence. Among other likely explanations, these antigens
may contain only discontinuous, or low prevalence epitopes.
Low prevalence of epitopes may be explained by the genetic
heterogeneity of infecting parasites (50). Future studies using
diverse serum samples (e.g. from diverse geographic origins,
or from patients displaying different clinical manifestations of
the disease) will help to answer this. We also note that the only
epitopes that are readily mimicked by synthetic peptides are
continuous epitopes. Discontinuous epitopes, which are
made up of residues from separate stretches of the antigen
polypeptide chain, can only be identified by x-ray crystallog-
raphy of antigen-antibody complexes. However, we believe
this limitation is largely balanced by the throughput and flex-
ibility offered by high-density peptide microarrays.
For many of these screenings seeking to identify antigens
or defined antigenic determinants, a number of bioinformatic
strategies based on defined protein features have been ap-
plied to narrow down the set of candidates displayed in the
arrays (25, 51–53). We have previously developed one such
strategy to prioritize T. cruzi proteins and peptides for use in
a spotted peptide microarray (25). In this work we found a
significant 6 fold increment in the number of seroreactive
peptides in this ranked set when compared with a random
pick, thus supporting the utility of such approaches.
In these experiments, we used a HD-Chip design were we
simultaneously measured antibody-binding to 200,000 ad-
dressable spots in each slide. However, larger capacities
(currently up to two million addressable spots) are possible by
using a single mirror per peptide field. In this case, the larger
capacity comes at the price of smaller fields and inherent
larger measurement error. However, even using larger pep-
tides fields, the screened protein space can be increased
significantly by decreasing the sequence overlap between
adjacent peptides in a protein sequence. The high signal
correlation observed from peptides that are contiguous in the
protein sequence suggested that it could be possible to fur-
ther reduce the number of peptides required to completely
scan each protein. In a posteriori computational experiments
in which we re-analyzed the data simulating different peptide
overlaps, we observed no significant epitope mapping per-
formance loss down to an overlap of 12 residues between two
15-mers (i.e. a 3 residue shift when scanning a protein se-
quence) (not shown). This means that we should be able to
achieve a threefold increase in the protein search space
using the same number of peptides per slide. Considering a
large proteome such as that of T. cruzi, 33 HD-Chips would be
required to screen the 6 million 15-mers in which this pro-
teome can be broken down (200K peptide fields per chip,
scanning proteins at maximal resolution). However, by scan-
ning proteins with a 12-residue overlap and pushing the mi-
croarray density up to 500K peptides per slide, the complete
proteome could be covered with only four HD-Chips, without
sacrificing significant sensitivity.
In conclusion, by taking advantage of next-generation
peptide arrays, we show that by screening 3% a large
eukaryotic proteome we discovered and finely mapped
more than 120 new antigenic determinants, providing es-
sentially most of the linear B-cell epitopes currently known
for this infectious disease. Our results show that it is now
feasible to increase the pace of biomarker discovery for
infectious diseases, and to further increase the scale and
detail in the study of B-cell immune responses against
human infectious diseases.
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